An MRI-based dose-response analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial

Brachytherapy

Volumn 12, Issue 3, 2013, Pages 210-216

  Register, Steven P ^a   Kudchadker, Rajat J ^b   Levy, Lawrence B ^b   Swanson, David A ^b   Pugh, Thomas J ^b   Bruno, Teresa L ^b   Frank, Steven J ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Expanded prostate cancer index composite survey; Health related quality of life; MRI CT

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLADDER FUNCTION; BLADDER IRRITATION; BLADDER SPHINCTER; BRACHYTHERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GLEASON SCORE; HISTOGRAM; HUMAN; MALE; MONOTHERAPY; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RADIATION RESPONSE; THREE DIMENSIONAL IMAGING; TREATMENT PLANNING; URINARY URGENCY; URINE INCONTINENCE; BLADDER; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; MICTURITION; PATHOPHYSIOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINATION DISORDERS;

AGED; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY DOSAGE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; URINARY BLADDER; URINATION; URINATION DISORDERS;

EID: 84876727954     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2012.10.006     Document Type: Article

References (17)

1. Cancer Facts & Figures 2013 2013, American Cancer Society, American Cancer Society, Atlanta.
2. Bill-Axelson A., Holmberg L., Filen F., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst 2008, 100:1144-1154.
3. Wong Y.N., Mitra N., Hudes G., et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006, 296:2683-2693.
4. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
5. Eade T.N., Horwitz E.M., Ruth K., et al. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys 2008, 71:338-345.
6. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:25-33.
7. Parsons B.A., Evans S., Wright M.P. Prostate cancer and urinary incontinence. Maturitas 2009, 63:323-328.
8. Allen Z.A., Merrick G.S., Butler W.M., et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys 2005, 62:981-987.
9. Crook J.M., Potters L., Stock R.G., et al. Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk. Brachytherapy 2005, 4:186-194.
10. McLaughlin P.W., Troyer S., Berri S., et al. Functional anatomy of the prostate: Implications for treatment planning. Int J Radiat Oncol Biol Phys 2005, 63:479-491.
11. Merrick G.S., Butler W.M., Wallner K.E., et al. The impact of radiation dose to the urethra on brachytherapy-related dysuria. Brachytherapy 2005, 4:45-50.
12. Neill M., Studer G., Le L., et al. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. Brachytherapy 2007, 6:173-179.
13. Pinkawa M., Fischedick K., Piroth M.D., et al. Health-related quality of life after permanent interstitial brachytherapy for prostate cancer: Correlation with postimplant CT scan parameters. Strahlenther Onkol 2006, 182:660-665.
14. Anderson J.F., Swanson D.A., Levy L.B., et al. Urinary side effects and complications after permanent prostate brachytherapy: The MD Anderson Cancer Center experience. Urology 2009, 74:601-605.
15. Pardo Y., Guedea F., Aguilo F., et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 2010, 28:4687-4696.
16. Frank S.J., Stafford R.J., Bankson J.A., et al. A novel MRI marker for prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008, 71:5-8.
17. Frank S.J., Tailor R.C., Kudchadker R.J., et al. Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRI-based prostate brachytherapy. Med Dosim 2011, 36:200-205.